Related Experiment Video

Updated: May 28, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

SCaMC-1 promotes cancer cell survival by desensitizing mitochondrial permeability transition via ATP/ADP-mediated

J Traba1, A Del Arco, M R Duchen

  • 1Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, CIBER de Enfermedades Raras, Universidad Autónoma, Madrid, Spain.

Cell Death and Differentiation
|October 22, 2011
PubMed

Insights

The mitochondrial carrier SCaMC-1 regulates calcium buffering, desensitizing cells to stress-induced death. SCaMC-1 overexpression in cancer cells suggests it as a potential therapeutic target.

Area of Science:

  • Cell Biology
  • Mitochondrial Function
  • Cancer Biology

Background:

  • Mitochondrial permeability transition (mPT) is a key pathway in cell death across pathologies.
  • Regulation of mPT in intact cells remains poorly understood.
  • Calcium (Ca2+) plays a critical role in cellular stress responses.

Purpose of the Study:

  • To investigate the role of the mitochondrial carrier SCaMC-1/SLC25A24 in regulating Ca2+-mediated mPT.
  • To explore the function of SCaMC-1 in cellular Ca2+ buffering and cell death pathways.
  • To assess the potential of SCaMC-1 as a therapeutic target in cancer.

Main Methods:

  • Investigated SCaMC-1/SLC25A24 function in mediating mitochondrial ATP-Mg2-/Pi2- and HADP2-/Pi2- uptake.
  • Analyzed the effect of SCaMC-1 on mitochondrial Ca2+ buffering capacity.
  • Conducted gene expression analysis to identify SCaMC-1 expression patterns in cancer cells.
  • Utilized gene knockdown to assess the impact on cell death sensitivity.

Main Results:

  • SCaMC-1 mediates the uptake of ATP-Mg2-/Pi2- and HADP2-/Pi2- into mitochondria following cytosolic Ca2+ increase.
  • Mitochondrial ATP and ADP act as Ca2+ buffers, desensitizing the mPT.
  • SCaMC-1 is overexpressed in transformed and cancer cells.
  • SCaMC-1 knockdown significantly reduced mitochondrial Ca2+ buffering and sensitized cells to necrotic death.

Conclusions:

  • SCaMC-1 functions as a negative feedback regulator between cellular Ca2+ overload and mPT-dependent cell death.
  • SCaMC-1 plays a crucial role in protecting cells from Ca2+-induced necrotic death.
  • SCaMC-1 represents a potential novel therapeutic target for cancer treatment.

More Related Videos

Transmitochondrial Cybrid Generation Using Cancer Cell Lines07:49

Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

Screening Ion Channels in Cancer Cells06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...